Former Arkansas School for Mathematics, Sciences, and the Arts student Claire Green, now attending Mississippi State ...

David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...

Scholar Rock, a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy and additional severe and debilitating ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly. Scholar Rock, a biopharma company ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and ...

Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.

Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.

That handily beat the S&P 500 index, which itself had a good trading session with a 1.7% advance. Bulking up Scholar Rock targets relatively uncommon disorders that might lack effective treatments.

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated look at SRRK stock and why I'm upgrading.

CAMBRIDGE, Mass., January 08, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...

Scholar Rock's cash burn was increasing - net losses between 2020 and 2023 were $ (86.5m), $ (132m), $ (135m), and $ (166m), and its share price had declined to ~$6.5 by October 2023.